Life Sciences Archive » June, 2014

Life Sciences - June, 2014

313 articles

• 11th Circ. Affirms Ex-Stiefel Worker's $1.5M Award
• Judge OKs $24.3M In Attys' Fees In Pfizer Pay-For-Delay Row
• Actavis, Forest Labs Give Up 4 Generics In FTC Settlement
• Supreme Court Won't Hear Teva Case Over CAFA Removals
• Bingham Snags Trio of Life Science Pros From Cooley
• Government Says Novartis Can't Escape FCA Kickback Suit
• Deals Rumor Mill: KKR, AbbVie, Fiat Chrysler
• Allergan Says Valeant Valuation Of New Eye Drug Falls Short
• Masimo Rival Didn't Own Blood-Testing Patent, Judge Says
• High Court Declines Damages Case Over Child Vaccine Death
• High Court Sends Amgen Stock-Drop Suit Back To 9th Circ.
• Pfizer Wins Exclusion Of Professor's Report In Zoloft MDL
• Justices Want SG's Take On Generic-Drug Labeling Case
• Making Denver An IP Hub: Benefits Of New USPTO Office
• Ex-SAC Trader Martoma Should Get Over 8 Years: Prosecutors
• Calif. Appeals Court Nixes Bristol-Myers Win In Kickback Row
• Ranbaxy Wins FDA Approval To Sell Generic Diovan
• Medicare Part D Prior Authorizations Come Under Fire
• Troutman Sanders Snags Seasoned Greenberg Traurig IP Atty
• 6th Circ. Spurns Novel Attack On Drugmakers In Darvocet MDL
• Halfway Into 2014, Pharma M&A Still Booming
• 23andMe Customers Ordered To Arbitrate False Ad Claims
• Allergan, Pershing Settle Suit Over Poison Pill
• Takeda, Lilly Say Prejudice Infected $9B Actos Verdict
• 4 Things Every Law Firm Should Do Upon A Cyberbreach
• Preemption Pendulum: Medical Products And Parallel Claims
• Sens. Urge Watchdogs To Inspect $53B Valeant-Allergan Play
• A Look At HHS' Newly Proposed Exclusion Rule: Part 2
• Merz Pays $600M For Ultrasound Facelift Co. Ulthera
• Pfizer Seeks Limits On Tylenol Order In Advil Ad Suit
• Surviving FCA Claims In Novartis Kickback Row To Stay Put
• Del. Judge Trims Unilife Investors' Claims Over Director Pay
• Newest Valeant Ally Plays Up Investor Muscle In M&A Fights
• CORRECTED: Omnicare Seals End To Insurer's FCA Suit
• PhRMA, AHA Urge Supreme Court To Curb FCA Penalties
• Europe Not The Only Inversion Destination For Deal Makers
• A Look At HHS' Newly Proposed Exclusion Rule: Part 1
• 5 Things To Know About FDA Response To Off-Label Petition
• Lessons From Luxembourg V. Genzyme
• J&J Wins Investor Suit Over Ex-CEO's $30M Salary
• ABA, IPO Call For More Claim Construction Deference
• FDA Warns Of Severe Side Effects In Popular Acne Products
• 9 Takeaways From Enforcers On Medicare Fraud Priorities
• Drug Challenged Under AIA Biz Method Review For 1st Time
• AbbVie, Shire Poised For M&A Battle As Tensions Flare
• Mass. Gov. Signs Biologic Substitution Bill Into Law
• SLK Expands Its Tampa IP Practice With Two New Hires
• Texas Attorney Can't Collect Fen-Phen Referral Judgment
• Otsuka Sues To Block Intas' Generic Abilify
• Medtronic Inversion Could Shave $4.2B Off Tax Load
• 6 Objectives China Has Set For Itself On Pediatric Drugs
• Valeant Takes Another Step Toward $53B Allergan Deal
• Goodwin Procter Adds Capital Markets Expert To NY Office
• Burned By MDL Judge, Takeda Finds Hope In State Courts
• Del. Court Sides With Alvogen In Novartis Patent Row
• FDA Issues Final Guidances On Nanotech In Food, Cosmetics
• GSK Blasts Teva's Use Of Pom Ruling To Nix False-Ad Suit
• NY's Muddled Medical Pot Bill Making Investors Paranoid
• Ex-Mylan VP Says He Was Axed Over Cephalon Whistleblowing
• Warning, Warranty Claims Cut From Ortho Birth Control Case
• 9th Circ. Stands By New GSK Trial After Gay Juror Ousting
• Niaspan Antitrust Injury Is 'Pure Speculation,' Judge Told
• Endo's $600M DAVA Deal Provides Case Study In Pharma M&A
• Medicare Supplier's Contract Breach Suit Gets Trimmed
• Two Whistleblowers Cut Out Of $193M Endo Settlement
• FDA Warns GSK Over Flu Vaccine Contamination
• Deals Rumor Mill: Ten Network, Loral, Scripps
• Avanir Sues Ranbaxy To Block Generic Nuedexta
• Provigil Judge Nixes Conspiracy Claims In Antitrust Suit
• Merck Supplement Patents Nixed In 1st Pharma AIA Reviews
• Fed Circ. Says Nordic's 'Children's DHA' Mark Is Generic
• Justices Won't Examine Preemption In Medtronic Injury Case
• FDA Balks At Black Box Warnings On Cholesterol Drugs
• Deals Rumor Mill: Shire, Monsanto, Lululemon
• FDA Ups Ante On Drug Inspections With Detention Authority
• Dentons Nabs Life Sciences Patent Ace For Houston Office
• Allergan Rejects Hostile $53B Bid From Valeant, Ackman
• Zoll Can't Use Double-Patenting Defense In Philips IP Spat
• 3 Lingering Questions About How Actavis Works
• 3rd Circ. Kills Cobalis Suit Over Hedge Fund Scheme
• 5 Ways To Contain The Chaos Of Mass Torts And MDLs
• High Court Told 'Public Use' Rule Nixes Pronova Patent
• Endo, Impax Nailed With New Generic Opana Antitrust Suit
• Dolly Creators Ask Fed. Circ. To Rethink Clone Patent Ruling
• Takeda Destroyed Evidence In $9B Cancer Suit, Judge Says
• Fed. Circ. Won't Revive UV Sterilization Patent Case
• FDA Loosens Grip In Latest Win For Digital Health Firms
• Drug Software Co. Can't Duck Warning Suit On Appeal
• Medtronic Leverages PR To Head Off Inversion Doubts
• Sanofi Chemo Drug May Make Patients Feel Drunk, FDA Says
• Shire Rejects AbbVie's $46B Offer In Latest Inversion Try
• Natrol Avoids False-Ad Class Action Over Enhancement Claims
• FDA Strengthens Blood Clot Warnings On Testosterone Drugs
• Reed Smith Adds 5 K&L Gates Product Liability Partners
• New FDA Database May Have Negative Consequences
• K&L Gates Patent Ace Joins IP Firm Lee & Hayes In Seattle
• Teva Urges 9th Circ. Panel To Keep Pain Med Suits Federal
• Bankrupt Natrol Can Pay Employees, But Trustee Bid Looms
• FTC Warns REMS Abuse Not Safe From Antitrust Law
• Purchasers Blast Wyeth's Immunity Bid In Pay-For-Delay Suit
• Chancery Fast-Tracks Ackman Suit Over Allergan Poison Pill
• 3rd Circ. Decision Deepens Split On Crucial FCA Rule
• Cuomo Hashes Out Medical Marijuana Deal With NY Pols
• US Says Fed. Circ. Must Show Claim Construction Deference
• Novartis Hits Mylan With Patent Suit Over Dementia Patch
• Philly Risperdal Plaintiffs Slam J&J Push For Time Bar
• Female Powerbrokers Q&A: Williams Mullen's McCarroll
• Smartphone Forensics: Tips From The E-Discovery Trenches
• UK-Based LLP Partners Now Enjoy More Protections
• Prioritize When Deposing Plaintiff 'FDA Experts'
• Where Pay-For-Delay Stands One Year After Actavis
• Chancery Won't Halt $658M Bid For Chelsea Therapeutics
• Judge Sides With Novartis In Dementia Patch Patent Row
• Scotland's Health Secretary Seeks Mesh Implant Suspension
• FDA Slaps Apotex Over Data Misconduct In India
• Masuda Funai Snags Patent Pro From Jenner & Block
• 9th Circ. Affirms Wyeth, Schwarz Wins In Nausea Med Row
• HHS Keeps 340B Orphan Drug Policy Despite Court Ruling
• Bayer Nabs $14.2B In Financing To Back Merck Deal
• Porter Wright Nets Diverse Squire Sanders Litigator In Ohio
• Female Powerbrokers Q&A: Bush Seyferth's Cheryl Bush
• Female Powerbrokers Q&A: Davis Wright's Kelli Sager
• Valeant Makes Good On Threat Of Hostile $53B Allergan Play
• USPTO Sets New Rules On Patent Terms After Novartis Ruling
• Merck Defeats Bellwether Case In Fosamax Femur-Injury MDL
• Patient Claims Genzyme Swapped Good Medicine For Bad
• FDA Social Media Guidance Gives Drug Promos An Opening
• Faster FDA Approval For Medical Devices Coming Soon
• Pa. Justices Slam State's $80M Drug Overpayment Award
• Gordon & Rees Adds Enviro, Toxic Tort Partner In NY
• Heller Ruling May Be Knockout Punch Against Jewel Claims
• Holland & Knight Adds Ex-Kirkland Partner To IP Group
• Teva Asks High Court To Ax Fed. Circ. Claim Construction Rule
• Deals Rumor Mill: Alstom, Medtronic, BP
• Valeant To Officially Launch Hostile $53B Allergan Play
• Still The Fastest Justice Anywhere
• Sideman & Bancroft Adds IP Pro From Duane Morris
• Female Powerbrokers Q&A: Proskauer's Monica Shilling
• Female Powerbrokers Q&A: Levine Sullivan's Gayle Sproul
• Ameritox Wins $15M In Millennium Drug-Testing Kickback Row
• Novartis Dodges Punitive Damages In Aredia-Zometa Suit
• CORRECTED: 'Cobra Sexual Energy' False Ad Class Wins Cert.
• Pfizer Says Nev. AG Hid Doc Destruction In Hormone Drug Suit
• Novartis Seeks Dismissal Of FCA Kickback Claims
• Lamictal Buyers Urge 3rd Circ. To Revive Pay-For-Delay Case
• UMass RNA Patent Row To Go Forward After High Court Snub
• Rader Resignation A Head Scratcher Despite Email Flap
• Jones Day Lands IP Pro From Paul Hastings In San Diego
• Merchant & Gould Dodges DQ In Patent Suit
• Dodd-Frank Shields Overseas Whistleblowers, 2nd Circ. Told
• FDA Chides Akrimax Over Weight-Loss Product Promos
• HHS May Dig In Heels On 340B Orphan Drug Rule
• 5th Circ. Continues Trend Against 'Innovator Liability'
• Medtronic Next To Try Inversion Despite Political Blowback
• Female Powerbrokers Q&A: Nexsen Pruet's Marguerite Willis
• Female Powerbrokers Q&A: Steptoe & Johnson's Flanery
• Olympus Targets ArthroCare In Poaching Suit
• 8th Circ. Boosts Medical Expert Testimony For Plaintiffs
• Biz Groups Tell NJ Justices Whistleblower Ruling Too Broad
• Rader Calls It Quits After Email To Weil Atty
• Taxation With Representation: Tax Counsel On The Deal
• Vivus Hits Actavis With Patent Suit Over Weight-Loss Drug
• Celgene Bid To Ax FCA Suit Is Premature, US Says
• Judge Told NJ Punitive Curbs Don't Apply To Risperdal Suits
• Takeaways From Fed Circ. Opinions In Roche V. Apotex
• Ackman Brings Allergan To Court Over Poison Pill
• Female Powerbrokers Q&A: Sterne Kessler's Eldora Ellison
• Female Powerbrokers Q&A: Ogletree Deakins' Melissa Bailey
• GSK To Pay $22M To End Diabetic Drug Marketing Row
• Ex-Synthes Manager Breached Noncompete, Judge Says
• EU Pauses Zimmer's $13.4B Biomet Deal Over Missing Data
• Fed. Circ. Upholds Ruling Nixing BMS Hepatitis Drug Patent
• Eli Lilly Ducks Perjury Sanctions In $9B Actos Case
• Glenmark Suit Slams Ferring's Tactics Over Antidiuretic
• Adopt Value Or Be Left In The Ash Heap Of History
• Girardi Keese To Appeal GSK Avandia Fee Holdbacks
• CVS, Rite Aid Dodge Mich. False Claims Suits Over Generics
• Female Powerbrokers Q&A: Gordon & Rees' Leslie Benitez
• Female Powerbrokers Q&A: Bryan Cave's Chris Cesare
• The Rise Of Chemical Practice At ITC: 10 Considerations
• USPTO Training Memo Lacks Sound Basis In The Law
• ITC Stays Ban On Digital Data Imports In Dental Patent Suit
• Blue Cross Sues Takeda, Eli Lilly Over Actos Cancer Costs
• ACLU Fights Myriad's Bid For Cancer-Test Sales Ban
• Dietary Supplement Co. Natrol Enters Ch. 11
• NJ Groups Ask High Court To Widen Whistleblower Protections
• 'Routine' Means 'Necessary' For Section 101
• Lessons For Contractors From The Medtronic Settlement
• The Hidden Costs Of Spreadsheets In Risk Management
• FDA To Overhaul Device Office After Outside Critique
• NC Pols Nix Planned Curbs To Suits Over FDA-Approved Drugs
• Novartis Gets FCA Kickback Suit Pared Down
• Novartis Bone Drug Suit In Wrong Court, Judge Reiterates
• FDA Unveils Checklist For Generic Drug Approvals
• J&J Blasts Reconsideration Bid On Pa. Risperdal Punitives
• Female Powerbrokers Q&A: Gardere's Kim Yelkin
• Valeant Counters Allergan R&D Claims As Hostile Play Looms
• Female Powerbrokers Q&A: Proskauer's Margaret Dale
• 1st Circ. Affirms Dismissal of Abiomed Shareholder Suit
• PhRMA, BIO Seek Full Fed. Circ. Review Of Suprep Patent Row
• No Retrial For Atty Who Ran Stock Scheme With Ex-NFLer
• Generics Cos. Infringed Lysteda IP, Fed. Circ. Told
• NJ Pot Dispenser Wants Law Firm's Fee Demands Smoked
• FDA Partly Finalizes Guidance On Unique Device IDs
• Fed. Circ. Ends Sales Ban On Generic Latisse
• FDA Floats 1st Guidance On Track And Trace
• FDA Asks Court To Halt Sales By NY Diet Supplement Co.
• J&J Can't Remove Xarelto Defect Suit Out Of Philly
• PhRMA V. HHS Scales Back HRSA Rulemaking Power
• Female Powerbrokers Q&A: Thacker Martinsek's Martinsek
• Female Powerbrokers Q&A: Rutan & Tucker's Kathy Jenson
• O'Melveny Lands Deals Pro For Silicon Valley Office
• High Stakes In Ascertainability Of Low-Dollar Purchases
• Valeant, Ackman To Go Hostile As Allergan Spurns $53B Bid
• High Court Passes On Galderma's Acne Gel Patent Fight
• Cephalon Can't Boot Outside Firm From Off-Label Suit
• Anulex Escapes Off-Label Suture Suit
• LA Marijuana Shops' Equal Protection Suit Sputters Again
• 2nd Circ. Affirms Dismissal Of Adderall Pay-For-Delay Suit
• Novartis Beats Zometa Jaw Injury Row In New Jersey
• FDA Finalizes Rule On Electronic Drug Safety Reports
• Paul Hastings Adds Ex-Finnegan Henderson IP Pro
• FDA OKs Off-Label Petitions By Sidley Austin, Ropes & Gray
• Ackman Defends Gray Area Bid for Allergan
• Fed. Circ. Affirms WL Gore's Win In Heart Device IP Row
• Deals Rumor Mill: Allergan, Credit Suisse, Alitalia
• The Purpose Of Proposed Rule 37(e)
• Merck Drops $3.85B On Hep C Drug Co. Idenix
• Nautilus: A Reliable Compass In The Sea Of Indefiniteness?
• Female Powerbrokers: WhatleyKallas' Edith Kallas
• Female Powerbrokers Q&A: Michael Best's Kerryann Minton
• Don't Let Barko Bite Atty-Client, Work-Product Privileges
• K-V Investors Can't Save Suit Over Pregnancy Drug
• Pfizer Wins 3rd Straight Asbestos Case Over Quigley Products
• Rader Email To Weil Atty Not Enough To Restart Cases
• FDA Puts Limits On Reprints Of Drug Risk Research
• Diagnostic Testing Fight Puts FDA In A Pickle
• 3rd Circ. Buries Pfizer Investor Suit Over Alzheimer's Med
• EU Says Ranbaxy India Site Safe, Despite FDA Warnings
• Endo, Impax Schemed To Delay Opana Generics, Suit Says
• Pa. Appeals Court Affirms J&J Win In Fentanyl Patch Suit
• Female Powerbrokers Q&A: Husch Blackwell's Hanaway
• Female Powerbrokers Q&A: Waller's Katie Stenberg
• Omnicare: The Other Securities Case To Be Worried About
• Standing Ruling May Chill AIA Reviews By Interest Groups
• $570M Boston Sci Contract Row Shoots Back To State Court
• Glenmark Seeks Rehearing Of $16M Tarka Patent Judgment
• Genzyme Escapes Investor Class Action Over Stock Plunge
• Pisgah Labs Demands $100M In Soured Painkiller Deal
• Latham & Watkins Lures Kirkland IP Pro To Chicago Office
• Patton Boggs, Squire Sanders Health Pros Head To Jones Day
• Merck Accused Of Advertising Bogus Sunscreen SPF Claims
• Keys To Successful Legal Outsourcing
• Senate Confirms Burwell To Lead HHS
• 7th Circ. Denies GSK's Appeal In Reed Smith Atty Suicide Case
• Donor Risks With Charity Patient Assistant Programs
• Female Powerbrokers Q&A: Brown Rudnick's Louise Verrill
• Female Powerbrokers Q&A: Duval & Stachenfeld's Terri Adler
• Fed. Circ. Lets Endo Opana Patent Win Stand
• PhRMA Booted From Suit Over Maine Drug Importation Law
• AstraZeneca Asthma Med Injunction Rolled Into Merits Trial
• $1.3M Atty Fees Refused As CreAgri Patent Row Not Baseless
• Glenmark Birth Control Recall Suit Revived In Ohio Court
• Anatomy Of A Merger War: Valeant, Ackman Vs. Allergan
• ACA Doesn't Lower Cost Of Most Expensive Meds, PhRMA Says
• Fleming Wants $3M Fen-Phen Referral Fee Award Slashed
• Wolff & Samson Boosts IP Group With Greenberg Traurig Pro
• Fed. Circ. Says Consumer Group Can't Fight Stem Cell Patent
• How Bitcoin Will Bring About A Legal Practice Revolution
• SEC Drops Insider Trading Suit Against MiMedx CEO
• Deals Rumor Mill: CVC, Lenovo, Hutchison
• GSK Forks Up $105M To End States' Off-Label Marketing Suits
• Senate Puts Burwell One Step Closer To Top HHS Role
• Pregnancy Test Maker Can't Escape False Ad Suit
• Female Powerbrokers Q&A: Akerman's Mary Carroll
• Female Powerbrokers Q&A: Hanson Bridgett's Linda Klamm
• Sandoz Gets Claims Nixed In UTC's Generic Remodulin Fight
• You Say 'Insolubly Ambiguous,' I Say 'Reasonably Certain'
• Ex-Merck VP Says No Proof He Lied About Vioxx Study
• Procaps Wins Half Of Requested Atty Fees In Patheon Fight
• Anda Escapes Doc Demands In 'Pill Mill' Suit Coverage Feud
• Calif. City Must Put Medical Pot On Ballot, 9th Circ. Told
• Pa. Judge Asked To Rethink Barring Risperdal Punitives
• FDA Criticizes Quality Control At Wockhardt's US Unit
• PR Tax Credit Can Withstand Company Sales, 1st Circ. Says
• Chicago Sues Pharma Cos. Over Painkiller Marketing
• Myriad, Prometheus Pushing Life Sciences Cos. To Licensing
• How To Control Your Law Firm's Real Estate Costs
• CORRECTED: Teva to Buy Migraine Treatment Co. in $825M Deal
• 5 Insights From Nationwide Chief Legal Officer Pat Hatler
• Female Powerbrokers Q&A: Fross Zelnick's Barbara Solomon
• Countering The Surge In Cosmetic Class Actions
• Jury Convicts ArthroCare Execs In $400M Fraud Scheme
• High Court Indefiniteness Test Will Spur Rush To Nix Patents
• Lawyers Weigh In On High Court's Patent Indefiniteness Ruling
• Ex-DaVita Staffers Fight To Keep FCA Suit Alive
• Ropes & Gray Settles Malpractice Suit Over Patent Delay
• A Close Look At High Court Decision In Limelight V. Akamai
• DePuy 'Raided' Howmedica Sales Team, $3M Suit Says
• Deals Rumor Mill: Google, Cinven, Protective Life
• Creative Collaborations: Law Firms And Corporations
• FTC's Pharma Patent Regulations Upheld
• PE-Backed Sterigenics Raises Nordion Bid To $805M
• Ex-Alcon Exec Presses Justices For Benefit Denial Rules
• FDA Unveils Huge Database Of Adverse Events
• Mylan Strikes Deal With Pfizer To Sell Generic Celebrex
• Medtronic Says US Has It Wrong On Device Claim Preemption
• Roche Swings $350M Deal To Buy DNA Sequencing Co. Genia
• GSK Teams With Biotech Co. On $350M Cancer Drug Venture
• Female Powerbrokers Q&A: Sugarman Rogers' Chris Netski
• Female Powerbrokers Q&A: Benesch's Megan Mehalko
• Ackman Launches Allergan Proxy Fight Amid $53B Buyout Play
• High Court Clears Way For More Challenges To Vague Patents